BioSpace News Archive

Theseus Pharmaceuticals, Inc. today announced U.S. Food and Drug Administration (FDA) clearance of an investigational new drug (IND) application to evaluate THE-630

Rivus Pharmaceuticals Inc. today announced positive results from both single and multiple ascending dose portions of its Phase 1 clinical trial of HU6. HU6, a first-in-class, orally administered Controlled Metabolic Accelerator (CMA) therapy

Repro Med Systems, Inc. dba KORU Medical Systems today announced the appointment of two new leaders who will be responsible for key elements of the Company’s growth strategy: Rob Cannon as the Company’s new Vice President of Sales, and Brian Hertzog as the Company’s new Vice President of BioPharma Business Development.

A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development of first-in-class T cell therapies to treat solid tumors.

Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the United States Food and Drug Administration (“FDA”) has accepted for review the Biologics License Application (“BLA”) for toripalimab in combination with gemcitabine and cisplatin for the first-line treatment for patients with advanced recurrent or nasopharyngeal carcinoma (“NPC”)

Todos Medical, Ltd. today announced it is now adding the Hillel Yaffe Medical Center as the 2nd clinical trial site in Hadera, Israel for its ongoing Tollovir® Phase 2 randomized, double blind, placebo controlled clinical trial for the treatment of hospitalized COVID-19 patients.

Prof. Niraj Varma & Dr. Kevin Campbell will help guide the development of new products as the company expands capabilities and continues to lead innovation in remote monitoring and AI

Titan Medical Inc. today announced that the company plans to issue its third quarter 2021 financial results prior to market opening on Thursday, November 11, 2021.

Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical devices, presented at the Symposium on Advanced Wound Care (SAWC) during the “Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care” session on October 31, 2021.

Reata Pharmaceuticals, Inc. today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on November 8, 2021.